Overview
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated.
MH002 is a live biotherapeutic product (LBP). This is a biological medicine containing live bacteria used to restore the normal function of a gut that is damaged by ulcerative colitis (UC). Ulcerative colitis is a bowel disease that causes inflammation and sores in the gut.
Eligibility
Inclusion Criteria:
- SCI ASIA: A, B, C,D
- Between 20 and 70 year of age
- \>1 year post SCI
- Complete or incomplete spinal cord injury.
- Expected will undergo spinal cord stimulation surgery.
- Continued rehabilitation after surgery for spinal cord injury.
- Able to comply with procedures and follow up.
- Stable medical condition without cardiopulmonary disease or dysautonomia that would - contraindicate participation in lower extremity rehabilitation or testing activities
Exclusion Criteria:
- Have significant cognitive impairment (MMSE\<24).
- Had a mental illness within one year or been treated in the past.
- Have Major depressive disorder.
- Active cancer diagnosis.
- Painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore, or urinary tract infection that might interfere with stand or step training.
- Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention.
- Unable to read and/or comprehend the consent form.
- Have concerns about this trial and do not sign consent.
